Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 2618

Next Previous
Drug Profile

TQB 2618

Alternative Names: TQB-2618

Latest Information Update: 04 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Nasopharyngeal cancer
  • Phase I/II Lymphoma; Squamous cell cancer
  • Phase I Colorectal cancer; Liver cancer; Non-small cell lung cancer
  • No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 16 Jul 2025 Chia Tai Tianqing Pharmaceutical terminates phase-I/II clinical trials in Squamous cell cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Inoperable/Unresectable) in China (Parenteral) due to business reasons (NCT05834543)
  • 04 Jun 2025 Chia Tai Tianqing Pharmaceutical Group terminates a phase-Ib trial in Liver cancer (First-line therapy, Combination therapy, Late-stage disease) in China (IV) (NCT05975645) due to business reasons, but no safety and efficacy concerns
  • 30 May 2025 Efficacy and adverse events data from a phase II trial in Nasopharyngeal carcinoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top